[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406119-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-406119-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","real-world-experience-of-guselkumab-in-the-elderly-population-original-research","Real-World Experience of Guselkumab in the Elderly Population - Original Research","","Retrospective analysis evaluates long-term effectiveness and safety of guselkumab in adults aged 65 years and older with plaque psoriasis. Sixty-six patients received guselkumab 100 mg from June 2019 to June 2024, with PASI measured at multiple follow-up points through week 104. Mean PASI fell from 13.3 at baseline to 1.0 by week 24 and remained stable thereafter. PASI90 and PASI100 were achieved by 83.9% and 71.0% at week 36 and persisted at week 104, while treatment-emergent adverse events occurred in 16.7%.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/real-world-experience-of-guselkumab-in-the-elderly-population-original-research/406119/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/real-world-experience-of-guselkumab-in-the-elderly-population-original-research/406119.png","ImageObject",300,407,{"name":42,"@type":43},"Aria Callaghan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the patient population and treatment regimen in this study?","Question",{"text":63,"@type":64},"The study included 66 patients aged 65 years and older with plaque psoriasis treated with guselkumab 100 mg between June 2019 and June 2024.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were effectiveness outcomes measured over time?",{"text":68,"@type":64},"Effectiveness was assessed using PASI scores recorded at baseline and during follow-up visits, with PASI75/90/100 and PASI ≤ 2 responses as key outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"What safety findings were reported for guselkumab in older adults?",{"text":72,"@type":64},"Treatment-emergent adverse events occurred in 16.7% of patients, with treatment discontinued in 9.1%. Eczematous or urticarial adverse events were associated with elevated baseline eosinophils and ELR.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},406119,1790760045,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Psoriasis: Targets and Therapy  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nReal-World Experience of Guselkumab in the Elderly Population  \nZeno Fratton 1 , Stefano Bighetti 2 , Luca Bettolini 2 , Vincenzo Maione2 , Mariateresa Rossi2 , Marina Venturini 2 , Vanessa Mazzoletti 3 , Enrico Zelin 3 , Giuseppe Stinco 1 , Enzo Errichetti 1  \n1Institute of Dermatology, Department of Medicine, University of Udine, Udine, Italy; 2Dermatology Department, University of Brescia, ASST Spedali Civili Di Brescia, Brescia, Italy; 3Institute of Dermatology, Santa Maria Della Misericordia University Hospital, Udine, Italy  \nCorrespondence: Zeno Fratton, Institute of Dermatology, Department of Medicine, University of Udine, Piazzale Santa Maria della Misericordia, 15, Udine, 33100, Italy, Tel +39 0432559820, Email [zenofratton@gmail.com](zenofratton@gmail.com)  \n\n| Introduction: Psoriasis is a chronic inflammatory disease whose burden peaks in older age groups. Despite the increasing prevalence of elderly patients with moderate-to-severe psoriasis, real-world data on biologics in this population remain limited, particularly for anti-IL-23 agents like guselkumab. This study evaluates the long-term effectiveness and safety of guselkumab in patients aged ≥65 years.\u003Cbr>Methods: This retrospective study included 66 patients aged ≥65 years with plaque psoriasis treated with guselkumab 100 mg between June 2019 and June 2024. PASI scores were recorded at baseline and during follow-up visits at weeks 4, 16, 24, 36, 52, 76, and 104. Effectiveness was assessed using PASI75/90/100 and PASI ≤ 2 responses. Multivariable logistic regression with Firth correction identified baseline predictors of PASI90 and PASI100 at weeks 16 and 52. Safety outcomes included treatment-emergent adverse events (TEAEs) .\u003Cbr>Results: Mean PASI improved from 13.3 at baseline to 1.0 at week 24 and remained stable through week 104. PASI90 and PASI100 were achieved by 83.9% and 71.0% at week 36 and maintained in 69.2% and 61.5% at week 104. Higher baseline PASI independently predicted PASI90 and PASI100 at week 16, while lower eosinophil-to-lymphocyte ratio (ELR) independently predicted PASI100 . At week 52, chronic beta-blocker intake and PASI90 at week 16 predicted PASI90 response, while PASI100 was independently associated with low-dose aspirin use and positive family history of psoriasis. TEAEs occurred in 16.7% of patients, with treatment discontinued in 9.1% . Eczematous or urticarial AEs were associated with elevated baseline eosinophils and ELR.\u003Cbr>Conclusion: Guselkumab is effective and well tolerated in older adults with psoriasis. Baseline ELR, early PASI response, and chronic use of beta-blockers or aspirin may influence long-term treatment outcomes. While limited by the small sample size (66 patients), our findings represent the longest real-world follow-up to date among older psoriatic patients treated with guselkumab and support its use as a valuable therapeutic option in this population.\u003Cbr>Keywords: guselkumab, efficacy, safety, elderly, over 65 year |\n| --- |\n| Introduction\u003Cbr>Psoriasis, a chronic inflammatory skin condition affecting 2–3% of the world population, 1 impacts quality of life and has the highest burden in the age groups of 60–64 and 65–69 years.2 A few studies have tried to estimate the exact prevalence of psoriasis in older adults,3,4 finding that between 3.9% and 5.3% are affected by the disease. Given that individuals with psoriasis have a life expectancy comparable to the general population and, considering the projected growth of the elderly demographic worldwide,5 the prevalence of psoriasis among older adults is expected to rise in the coming decades.\u003Cbr>Biologics have emerged as the treatment of choice in patients with moderate-to-severe psoriasis, especially in cases where conventional therapies, like cyclosporine or methotrexate, are contraindicated due to comorbidities. On the other hand, while the elderly have a higher multimorbidi","cbCaioZbFWNbhsUi","https://ap.wps.com/l/cbCaioZbFWNbhsUi","pdf",1953579,21,"English","# Introduction\n## Treatment context and clinical trial gaps\n# Methods\n## Study design, population, and endpoints\n# Results\n## Effectiveness outcomes and predictors\n## Safety outcomes and associated factors\n# Conclusion","[{\"question\":\"What was the patient population and treatment regimen in this study?\",\"answer\":\"The study included 66 patients aged 65 years and older with plaque psoriasis treated with guselkumab 100 mg between June 2019 and June 2024.\"},{\"question\":\"How were effectiveness outcomes measured over time?\",\"answer\":\"Effectiveness was assessed using PASI scores recorded at baseline and during follow-up visits, with PASI75/90/100 and PASI ≤ 2 responses as key outcomes.\"},{\"question\":\"What safety findings were reported for guselkumab in older adults?\",\"answer\":\"Treatment-emergent adverse events occurred in 16.7% of patients, with treatment discontinued in 9.1%. Eczematous or urticarial adverse events were associated with elevated baseline eosinophils and ELR.\"}]","Real-World Experience of Guselkumab in the Elderly Population - Original Research | PDF",1790563631,53]